Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

I am a UK healthcare professional No, take me back
UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2101574 August 2021

INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY

Trimbow® for Adult Asthma Overview

Dosing & Device

Costing

Evidence

Prescribing Information

General Resources

Request a Representative

Think triple (ICS/LABA/LAMA),
think Trimbow

The only extrafine formulation ICS/LABA/LAMA

combination1,2

Designed to reach the large and small airways1,3


Trimbow pMDI 87/5/9 is indicated for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.1

Trimbow® Device

Each dose contains three compounds for the treatment of asthma:1

  • Beclometasone
  • Formoterol
  • Glycopyrronium

Trimbow is licensed for adult asthma patients uncontrolled on medium dose ICS/LABA who have experienced an exacerbation in the previous year1

Extrafine formulation like Fostair® (beclometasone/formoterol)1,4

Familiar pMDI device, b.d. dosing and licensed for use with an AeroChamber Plus® spacer1,5,6

Reduction in moderate and severe exacerbations vs. medium dose ICS/LABA (Fostair pMDI 100/6)1,7

To request a visit from a Chiesi representative to learn more about Trimbow, please click here.

For additional information to share with your patients who have been prescribed Trimbow, please visit our Trimbow patient and carer site.

b.d.: twice daily; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; 

pMDI: pressurised metered dose inhaler.

References:
1. Trimbow pMDI 87/5/9 Summary of Product Characteristics. Chiesi Limited.
2. MIMS online. 2021. Available at: www.mims.co.uk.
3. Singh D et al. Tuberc Respir Dis. 2017; 80: 317–324.
4. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
5. R3F market data. IQVIA LPD. MAT May 2021.
6. IQVIA XBPI data. MAT June 2021.
7. Virchow JC et al. Lancet. 2019; 394(10210): 1737–1749.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.